“In America, most of the learning that occurs in healthcare is in clinical trials,” Turner said. Yet a full 96 percent of patients do not participate. “It’s a huge problem: If 100 patients walk in the door, we’re only learning from four of them.”
他说:“在美国,绝大多数癌症治疗经验都来自于临床试验。”但是高达96%的病人并不参加这类试验。“这是个大问题,也就是说,100个进医院的病人中只有4个人可以供我们深入研究。”
Information is certainly collected on the other 96%—but it is typically trapped in electronic medical records (EMR) systems and doctors’ notes, Turner said. “Our vision is to aggregate the data on that 96 percent, organize it, and make it usable by physicians, patients, and any of the stakeholders here,” he said. “Ultimately, we want to improve cancer care.”
另外96%的病人信息其实也有人收集——但特纳称,它们往往沉淀在电子病历(EMR)系统和医生笔记里。“我们的目标就是收集这96%的病人的数据,重新整理,让它们可以为医生、病人和其他利益相关者所用。说到底,我们是希望能提高癌症的治疗水平。”
‘Their concern is longevity’
“谷歌想要的就是长生不老”
Flatiron’s OncologyCloud platform includes an analytics section, an EMR piece that comes courtesy of the company’s recent acquisition of Altos Solutions, a patient portal, and a billing portion. Together, the technologies provide what the company calls the world’s largest single source of structured real-world oncology data and intelligence. By enabling that data to be shared in HIPAA-compliant ways, Flatiron hopes it will accelerate personalized medicine and research.
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15